Search results
Showing 76 to 90 of 147 results for atrial fibrillation
PleuraFlow Active Clearance Technology for maintaining chest tube patency (MIB125)
NICE has developed a medtech innovation briefing (MIB) on PleuraFlow Active Clearance Technology for maintaining chest tube patency .
subclinical hyperthyroidism is associated with an increased risk of atrial fibrillation, osteoporosis, dementia, and death, including...
Atrial fibrillation - clopidogrel (in combination with aspirin) [ID95]
Discontinued Reference number: GID-TAG416
Leadless cardiac pacemaker implantation for bradyarrhythmias (HTG770)
Evidence-based recommendations on leadless cardiac pacemaker implantation for bradyarrhythmias. This involves implanting a cardiac pacemaker that does not have leads directly into the internal wall of the heart.
View recommendations for HTG770Show all sections
preventing stroke and systemic embolism in people with non-valvular atrial fibrillation Number TA275 Date issued February 2013
preventing stroke and systemic embolism in people with non-valvular atrial fibrillation Number TA275 Date issued February 2013
Percutaneous closure of patent foramen ovale to prevent recurrent cerebral embolic events (HTG325)
Evidence-based recommendations on percutaneous closure of the patent foramen ovale for the prevention of cerebral embolic stroke. This involves placing a small device into the heart to close the hole.
Evidence-based recommendations on clopidogrel and modified-release dipyridamole for preventing occlusive vascular events in adults.
Evidence-based recommendations on CorVue (Abbott Medical), HeartInsight (Biotronik), HeartLogic (Boston Scientific) and TriageHF (Medtronic) for algorithm-based remote monitoring in people with cardiac implantable electronic devices.
Dapagliflozin for treating chronic heart failure with reduced ejection fraction (TA679)
Evidence-based recommendations on dapagliflozin (Forxiga) for symptomatic chronic heart failure with reduced ejection fraction in adults.
Zanubrutinib for treating chronic lymphocytic leukaemia (TA931)
Evidence-based recommendations on zanubrutinib (Brukinsa) for treating chronic lymphocytic leukaemia in adults.
Cardiovascular risk assessment and lipid modification (QS100)
This quality standard covers identifying and assessing cardiovascular risk in adults without cardiovascular disease, and treatment to prevent primary and secondary cardiovascular disease. It describes high-quality care in priority areas for improvement.
View quality statements for QS100Show all sections
Sections for QS100
- Quality statements
- Quality statement 1: Identifying adults who are likely to be at high risk
- Quality statement 2: Diet and lifestyle advice for primary prevention
- Quality statement 3: Lipid-lowering treatment for primary prevention
- Quality statement 4: Assessing response to lipid-lowering treatment
- Quality statement 5: Secondary prevention of cardiovascular disease
- Update information
- About this quality standard
Past technology appraisal appeals and decisions
Atrial fibrillation: The management of atrial fibrillation (CG36)
This guidance has been updated and replaced by NICE guideline CG180.
Irreversible electroporation for treating pancreatic cancer (HTG437)
Evidence-based recommendations on irreversible electroporation for treating pancreatic cancer. This involves inserting special needles into the tumour in the pancreas and using short electrical pulses to destroy the cancer cells.